PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,974,334 | -48.2% | 96,947 | -32.3% | 0.01% | -42.9% |
| Q2 2023 | $5,738,906 | +456.2% | 143,222 | +466.5% | 0.01% | +366.7% |
| Q1 2023 | $1,031,840 | -23.2% | 25,284 | +43.7% | 0.00% | -25.0% |
| Q1 2022 | $1,343,000 | -66.9% | 17,594 | -73.9% | 0.00% | -55.6% |
| Q4 2021 | $4,060,000 | -34.0% | 67,480 | -38.6% | 0.01% | -35.7% |
| Q3 2021 | $6,153,000 | -72.3% | 109,878 | -70.0% | 0.01% | -72.0% |
| Q2 2021 | $22,223,000 | +258.9% | 366,231 | +314.5% | 0.05% | +212.5% |
| Q1 2021 | $6,192,000 | +24.4% | 88,348 | +6.2% | 0.02% | +14.3% |
| Q4 2020 | $4,977,000 | -43.6% | 83,171 | -43.3% | 0.01% | -54.8% |
| Q3 2020 | $8,826,000 | +563.6% | 146,813 | +270.0% | 0.03% | +181.8% |
| Q1 2020 | $1,330,000 | -77.7% | 39,675 | -69.9% | 0.01% | -38.9% |
| Q4 2019 | $5,974,000 | -49.8% | 131,874 | -51.8% | 0.02% | -55.0% |
| Q2 2019 | $11,905,000 | +58.0% | 273,743 | +38.3% | 0.04% | +66.7% |
| Q1 2019 | $7,533,000 | -38.9% | 197,925 | -30.9% | 0.02% | -50.0% |
| Q4 2018 | $12,322,000 | +44.2% | 286,428 | +64.7% | 0.05% | +108.7% |
| Q3 2018 | $8,546,000 | +15.5% | 173,869 | +7.2% | 0.02% | -4.2% |
| Q4 2017 | $7,401,000 | +259.6% | 162,121 | +195.8% | 0.02% | +242.9% |
| Q3 2017 | $2,058,000 | -84.1% | 54,800 | -79.8% | 0.01% | -85.1% |
| Q2 2017 | $12,966,000 | +18.7% | 271,816 | +13.5% | 0.05% | +27.0% |
| Q1 2017 | $10,920,000 | +41.5% | 239,474 | +0.2% | 0.04% | +23.3% |
| Q4 2016 | $7,717,000 | +25.9% | 238,916 | +33.4% | 0.03% | +36.4% |
| Q3 2016 | $6,130,000 | -13.4% | 179,139 | -14.6% | 0.02% | -26.7% |
| Q2 2016 | $7,076,000 | +108.7% | 209,794 | +227.7% | 0.03% | +87.5% |
| Q1 2016 | $3,391,000 | +295.7% | 64,014 | +473.6% | 0.02% | +300.0% |
| Q4 2015 | $857,000 | +22.6% | 11,161 | -34.4% | 0.00% | 0.0% |
| Q3 2015 | $699,000 | -96.8% | 17,016 | -92.6% | 0.00% | -96.0% |
| Q3 2014 | $22,173,000 | +206.6% | 228,775 | +190.6% | 0.10% | +200.0% |
| Q2 2014 | $7,231,000 | +96.0% | 78,716 | +49.3% | 0.03% | +65.0% |
| Q1 2014 | $3,689,000 | – | 52,707 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |